Janssen Pharmaceutical Companies of Johnson & Johnson has stopped the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) clinical trial ahead of schedule after meeting the efficacy endpoints of the trial.

The decision follows a recommendation given by the trial’s Independent Data Monitoring Committee (IDMC) after completing a planned interim analysis of the study data.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

CREDENCE is a Phase lll study evaluating the efficacy and safety of Invokana (canagliflozin) versus placebo when used along with standard of care for the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).

The randomised, double-blind, placebo-controlled, parallel-group, multicentre trial enrolled around 4,400 patients with T2D.

All the patients were on the maximum labelled or tolerated dose of an ngiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB) for more than four weeks before randomisation.

“This huge unmet need is why it was so important for us to initiate the landmark CREDENCE renal outcomes trial over four years ago.”

The primary composite endpoint of the trial included end-stage kidney disease (time to dialysis or kidney transplantation), doubling of serum creatinine, and renal or cardiovascular (CV) death, when used along with standard of care.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

CREDENCE Steering Committee co-chair Vlado Perkovic said: “Nearly half of all people with type 2 diabetes will develop chronic kidney disease, causing a high risk of kidney failure and cardiovascular disease, and impacting their quality and length of life, even with the current best available care.

“This huge unmet need is why it was so important for us to initiate the landmark CREDENCE renal outcomes trial over four years ago.”

Invokana is currently suggested for lower blood sugar in adults with type 2 diabetes, but has not been prescribed for people with type 1 diabetes or with diabetic ketoacidosis (increased ketones in blood or urine).